Cancer23

Introducing a new personalised approach to cancer treatment pathways.

23Strands Cancer

We have partnered with the leading genomics providers to provide clinicians with personalised insights into alternative treatment options concerning their cancer patients.

OUR CAPABILITIES

Deep and extensive tumour gene expression analysis can generate relevant data that reveals possible targets for precision drug therapy.
Comprehensive genetic profiling of tumour tissue
Evaluate the effectiveness of responses and reactions to chemotherapy drugs
Provide efficacy and resistance guidance for chemotherapy
Deliver a non-invasive biopsy diagnostic tool through blood samples as an alternative substitute to invasive tissue extraction.

Research Documents

Files for Patients

Files for Doctors

Latest News

Keep up to date with the latest genomics news

Friday, August 18, 2023

Application of 23Strands’ AI-powered Platform in Identifying Gene-Lists for Endometriosis

In recent research, the technical capability of wholly Australian-owned bioinformatics start-up, 23Strands, to decipher big data about genomics is revolutionising scientific research in women’s health. 23Strands’ work in genomics was linked with known molecular pathways for endometriosis to identify key genes associated with the disease.